Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors

Stock Information for Sutro Biopharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Sutro Biopharma Inc.

Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference
Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development
Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study
Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights
Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026
Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights
Sutro Biopharma to Participate in Upcoming Investor Conferences
Sutro Biopharma Announces Participation at the 16th World ADC London Summit

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.